MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

About the study

This is a study to collect the outcomes of stem cell transplantation for patients with
hematologic diseases other than cancer.

Study point of contact

Lisa Burke
612-273-8482
[email protected]

Locations

1 United States site

Age

< 55 Years

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

participation requirements

– Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other
non-malignant hematologic disorders for which a stem cell transplant is indicated

– Acceptable stem cell source identified

– Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score)

– Creatinine <2.0 mg/dl for adults or glomerular filtration rate > 50 ml/min for
children

– Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase <5 times the upper limit of institutional normal - Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%

participation restrictions

– active, uncontrolled infection

– pregnant or breastfeeding

– HIV positive

Locations

  • Minneapolis, Minnesota, United States, University of Minnesota Medical Center, Fairview, 55455 [Recruiting]
Last updated 2021-09-10